Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Gastro-enteropancreatic neuroendocrine tumor 1Adenoma, Islet Cell 1

Interventions

Everolimus 6Sunitinib 3Octreotide 3cabozantinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Injections 2Fluorouracil 2Capecitabine 2Bevacizumab 2recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1motesanib diphosphate 1lanreotide 1ibrutinib 1ganitumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1belzutifan 1batifiban 1atezolizumab 1abemaciclib 1X-Rays 1Thalidomide 1Temozolomide 1Streptozocin 1Sorafenib 1Phantoms, Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenoma, Islet Cell × abemaciclib × Endocrine × Clear all
NCT03891784 2026-01-14

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

University of Washington

Phase 2 Active not recruiting
20 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡